## Supplemental Information

Q1 2017

Omega Healthcare Investors, Inc. is a Real Estate Investment Trust ("REIT") providing financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities located in the United States.

At March 31, 2017, the Company's portfolio of investments included 972 operating healthcare facilities, consisting of skilled nursing facilities, assisted living facilities and other specialty hospitals, located in 42 states (includes Manhattan 2nd Avenue project) and the UK ( 35 facilities), and operated by 77 third-party healthcare operating companies.

As a source of capital to the healthcare industry, Omega continually evaluates the opportunities, trends and challenges affecting the industry. Our goal is to identify long-term investments in quality healthcare properties with outstanding operators that provide the most favorable risk/reward ratio to our investors.

## TABLE OF CONTENTS

## Page

## Portfolio

Investment Summary............................................... 3
Revenue Summary 3
Payor Mix and Coverage Summary .....  3
Revenue Concentration by Operator .....  4
Lease and Mortgage Expirations .....  4
Diversification
Operator Geographic Diversification .....  5
Selected Metrics
Occupancy by State. .....  5
EBITDARM \& EBITDAR Coverage Stratification .....  6
EBITDAR Coverages less than 1.0x ..... 6
Investment Activity .....  7
Capitalization
Capital Structure and Rates .....  8
Debt Maturity Schedule .....  8
Senior Unsecured Debt Ratings .....  8
Selected Covenants and Ratios .....  .9
Equity Issuance Summary ..... 10
Book and Market Capitalization ..... 11
Financial Performance
Historical AFFO, FAD and Dividends. ..... 12
Current Year Guidance ..... 13
Quarterly Financials
Income Statements ..... 14
Balance Sheets ..... 15
Statements of Cash Flows ..... 16
Non-GAAP Reconciliations
Net Income, FFO, Adjusted FFO and FAD ..... 17
EBITDA and Debt Coverage Ratios ..... 19
EBITDA and FC and Interest Coverage Ratios. ..... 20
Selected Definitions ..... 21

Executive Officers<br>Taylor Pickett, President and Chief Executive Officer Dan Booth, Chief Operating Officer<br>Steven Insoft, Chief Corporate Development Officer<br>Bob Stephenson, Chief Financial Officer<br>Mike Ritz, Chief Accounting Officer<br>\section*{Board of Directors}<br>\section*{Bernard J. Korman, Chairman}<br>Craig M. Bernfield<br>Norman R. Bobins<br>Craig R. Callen<br>Barbara B. Hill<br>Edward Lowenthal<br>Stephen D. Plavin<br>Ben W. Perks<br>Taylor Pickett<br>Harold J. Kloosterman<br>\section*{Analysts}<br>Bank of America/Merrill Lynch....... Juan Sanabria.......... 646-855-1589<br>BTIG............................................. Michael Gorman..... 646-562-1320<br>Goldman Sachs............................. Andrew Rosivach.... 212-902-2796<br>Green Street Advisors.................... Michael Knott......... 949-640-8780<br>Hilliard Lyons.................................. John Roberts.......... 502-588-1165<br>Jeffries.......................................... Tayo Okusanya....... 212-336-7076<br>JMP Securities................................ Peter Martin........... 415-835-8900<br>Stifel Nicolaus................................. Chad Vanacore....... 518-587-2581<br>SunTrust...................................... Eric Fleming............ 617-345-6536<br>UBS.............................................. Nicholas Yulico........ 212-713-3402<br>Wells Fargo.................................. Todd Stender.......... 212-214-8067

| Stock Symbol: | OHI | Shares \& Units Outstanding March 31, 2017: | 205,575,196 |
| :--- | :--- | :--- | ---: |
| Exchange: | NYSE | CUSIP Number: | 681936100 |

Contact Information

## Omega Healthcare Investors, Inc.

303 International Circle
Suite 200
Hunt Valley, MD 21030
(410) 427-1700 (Main)
(866) 996-6342 (Investor Relations)
www.omegahealthcare.com

Transfer Agent Correspondence
Computershare, Inc.
P.O. Box 505000

Louisville, KY 40233
(800) 368-5948

This supplement includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Omega's or its tenants', operators', borrowers' or managers' expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, merger integration, growth opportunities, expected lease income, continued qualification as a REIT, plans and objectives of management for future operations and statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will" and other similar expressions are forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from Omega's expectations. Omega does not undertake a duty to update these forward-looking statements, which speak only as of the date on which they are made.

Omega's actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among other things: (i) uncertainties relating to the business operations of the operators of Omega's properties, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; (ii) regulatory and other changes in the healthcare sector; (iii) changes in the financial position of Omega's operators; (iv) the ability of any of Omega's operators in bankruptcy to reject unexpired lease obligations, modify the terms of Omega's mortgages and impede the ability of to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor's obligations; (v) the availability and cost of capital; (vi) changes in Omega's credit ratings and the ratings of its debt securities; (vii) competition in the financing of healthcare facilities; (viii) Omega's ability to maintain its status as a REIT; (ix) Omega's ability to manage, re-lease or sell any owned and operated facilities; (x) Omega's ability to sell closed or foreclosed assets on a timely basis and on terms that allow Omega to realize the carrying value of these assets; (xi) the effect of economic and market conditions generally, and particularly in the healthcare industry; (xii) the potential impact of changes in the SNF and ALF market or local real estate conditions on the Company's ability to dispose of assets held for sale for the anticipated proceeds or on a timely basis, or to redeploy the proceeds therefrom on favorable terms and (xiii) other factors identified in Omega's filings with the Securities and Exchange Commission. Statements regarding future events and developments and Omega's future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward looking statements. Omega undertakes no obligation to update any forward-looking statements contained in this supplement.

Operator Information: This supplement includes information regarding the operators of our facilities such as EBITDAR and EBITDARM coverage ratios. The information related to operators that is provided in this supplement has been provided by the operators. We have not independently verified this information. We are providing this data for informational purposes only.

Non-GAAP Information: This supplement also contains certain non-GAAP financial information including EBITDA, Adjusted Total Debt (or Funded Debt), Adjusted Book Capitalization, FFO, Adjusted FFO, Funds Available for Distribution ("FAD"), Total Cash Fixed Charges and certain related ratios. A reconciliation of these non-GAAP disclosures is available in the Financial Performance section of this supplement.

Information is provided as of March 31, 2017, unless specifically stated otherwise. We assume no duty to update or supplement the information provided.

## INVESTMENT SUMMARY

| (\$ in thousands) | As of March 31, 2017 |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Balance Sheet Data | Total No. of Properties |  | estment | \% of Investment | Total No. of Operating Properties (4) | No. of Operating Beds |  |
| Real Estate Investments ${ }^{(1)}$ | 869 | \$ | 7,600,865 | 86\% | 867 | 87,718 |  |
| Direct Financing Leases | 58 |  | 604,777 | 7\% | 57 | 5,695 |  |
| Loans Receivable | 49 |  | 641,501 | 7\% | 48 | 5,115 |  |
| Total Investments | 976 | \$ | 8,847,143 | 100\% | 972 | 98,528 |  |
| Investment Data | Total No. of Properties |  | estment | \% of Investment | Total No. of Operating Properties | No. of Operating Beds | Investment Per Bed |
| Skilled Nursing/Transitional Care ${ }^{(1)}$ | 861 | \$ | 7,558,759 | 85\% | 860 | 91,369 | \$83 |
| Senior Housing ${ }^{(3)}$ | 115 |  | 1,288,384 | 15\% | 112 | 7,159 | 180 |
|  | 976 | \$ | 8,847,143 | 100\% | 972 | 98,528 | \$90 |

(1) Includes a $\$ 19.2$ million lease inducement and excludes $\$ 23.2$ million of assets (nine properties) classified as assets held for sale
(2) Excludes properties classified as assets held for sale
(3) Includes ALFs, memory care and independent living facilities
(4) Excludes facilities which are non-operating, closed and/or not currently providing patient services

## Revenue Summary

(\$ in thousands)

Revenue by Investment Type

Rental Property
Direct Financing Leases
Mortgage Notes
Other Investment Income \& Misc Income

Revenue by Facility Type

Skilled Nursing / Transitional Care
Senior Housing
Other

| Three Months Ended |  |  |
| :---: | :---: | :---: |
| $3 / 31 / 2017$ |  |  |
| $\$$ | 192,537 | $83 \%$ |
|  | 15,646 | $7 \%$ |
|  | 15,956 | $7 \%$ |
|  | 7,605 | $3 \%$ |
| $\$$ | 231,744 | $100 \%$ |

Three Months Ended
3/31/2017

| \$ |  |  |
| :--- | ---: | ---: |
|  | 199,464 | $86 \%$ |
|  | 24,675 | $11 \%$ |
|  | 7,605 | $3 \%$ |
| $\$$ | 231,744 | $100 \%$ |

## Payor Mix and Coverage Summary

| Three Months Ended... | \% Revenue Mix |  |  | Twelve Months Ended... | Occ. \% ${ }^{(1)}$ | Coverage Data |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Medicaid | Medicare / <br> Insurance | Private / Other |  |  | EBITDARM | EBITDAR |
| December 31, 2016 | 52.6\% | 35.8\% | 11.6\% | December 31, 2016 | 82.2\% | 1.69x | 1.33x |
| September 30, 2016 | 53.0\% | 35.8\% | 11.2\% | September 30, 2016 | 82.1\% | 1.68x | 1.31x |
| June 30, 2016 | 51.8\% | 37.5\% | 10.7\% | June 30, 2016 | 82.1\% | 1.72x | 1.34 x |
| March 31, 2016 | 51.8\% | 38.6\% | 9.6\% | March 31, 2016 | 82.2\% | 1.75 x | 1.37x |
| December 31, 2015 | 53.1\% | 37.5\% | 9.4\% | December 31, 2015 | 82.5\% | 1.78 x | 1.40x |

(1) Based on available (operating) beds

## Revenue Concentration by Operator

(\$ in thousands)

1 Ciena
2 Signature
3 Genesis
4 Ark
5 Communicare
6 Saber
7 HHC
8 Maplewood
9 Guardian
10 Diversicare Remaining 67 Operators

No. of

| Properties | (1) | Revenue $^{(2)}$ | \% Revenue |
| ---: | ---: | ---: | ---: |
| 68 | $\$$ | 82,268 | $10 \%$ |
| 62 | 61,801 | $7 \%$ |  |
| 50 | 57,293 | $7 \%$ |  |
| 58 | 54,001 | $6 \%$ |  |
| 32 | 46,107 | $5 \%$ |  |
| 46 | 41,098 | $5 \%$ |  |
| 44 | 34,544 | $4 \%$ |  |
| 13 | 33,102 | $4 \%$ |  |
| 31 | 29,303 | $3 \%$ |  |
| 35 | 28,123 | $3 \%$ |  |
| 533 | 378,757 | $46 \%$ |  |
| 972 | $\$$ | 846,397 | $100.0 \%$ |

(1) Number of Properties excludes facilities which are non-operating, closed and/or not currently providing patient services
(2) 1Q 2017 rent and debt service annualized; includes mezzanine and term loan interest

## Lease and Mortgage Expirations

(\$ in thousands)

|  | Year | Contractual <br> Revenue Annualized |  | \% | Investment Amounts |  |  |  |  |  |  |  |  | Operating Facilites |  | Operating Beds |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Lease | Capital Lease |  | Mortgage |  | Total |  | \% | No. | \% | No. | \% |
| 1 | 2017 | \$ | 7,964 |  | 0.9\% | \$ | 95,054 | \$ | - | \$ | - | \$ | 95,054 | 1.1\% | 12 | 1.2\% | 957 | 1.0\% |
| 2 | 2018 |  | 39,741 | 4.7\% |  | 314,813 |  | - |  | 37,627 |  | 352,441 | 4.0\% | 52 | 5.3\% | 5,124 | 5.2\% |
| 3 | 2019 |  | 3,636 | 0.4\% |  | 38,423 |  | - |  | - |  | 38,423 | 0.4\% | 6 | 0.6\% | 406 | 0.4\% |
| 4 | 2020 |  | 14,055 | 1.7\% |  | 56,242 |  | 393 |  | 2,500 |  | 59,135 | 0.7\% | 10 | 1.0\% | 1,050 | 1.1\% |
| 5 | 2021 |  | 11,441 | 1.4\% |  | 118,422 |  | - |  | - |  | 118,422 | 1.3\% | 23 | 2.4\% | 1,153 | 1.2\% |
| 6 | 2022 |  | 68,584 | 8.1\% |  | 584,975 |  | - |  | - |  | 584,975 | 6.6\% | 86 | 8.8\% | 8,533 | 8.7\% |
| 7 | 2023 |  | 51,867 | 6.1\% |  | 504,803 |  | - |  | - |  | 504,803 | 5.7\% | 62 | 6.4\% | 6,680 | 6.8\% |
| 8 | 2024 |  | 64,507 | 7.6\% |  | 548,715 |  | - |  | 112,500 |  | 661,215 | 7.5\% | 64 | 6.6\% | 6,072 | 6.2\% |
| 9 | 2025 |  | 22,064 | 2.6\% |  | 204,086 |  | - |  | - |  | 204,086 | 2.3\% | 21 | 2.2\% | 2,829 | 2.9\% |
| 10 | 2026 |  | 24,729 | 2.9\% |  | 292,383 |  | - |  | - |  | 292,383 | 3.3\% | 35 | 3.6\% | 3,834 | 3.9\% |
|  | Thereafter |  | 537,809 | 63.5\% |  | 4,842,949 |  | 604,384 |  | 488,874 |  | 5,936,206 | 67.1\% | 601 | 61.8\% | 61,890 | 62.8\% |
|  | TOTAL | \$ | 846,397 | 100.0\% | \$ | 7,600,865 | \$ | 604,777 | \$ | 641,501 | \$ | 8,847,143 | 100.0\% | 972 | 100.0\% | 98,528 | 100.0\% |

Note: All percentages rounded to one decimal.



Geographic Concentration by Investment
(\$ in thousands)

|  | No. of Properties (1) | Total Investment ${ }^{(2)}$ |  | \% Investment |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Ohio | 87 |  | 843,813 | 9.5\% | 83.6\% |
| Texas | 109 | \$ | 786,418 | 8.9\% | 70.1\% |
| Florida | 95 |  | 783,921 | 8.9\% | 87.7\% |
| Michigan | 46 |  | 604,294 | 6.8\% | 85.9\% |
| California | 55 |  | 511,722 | 5.8\% | 92.7\% |
| Pennsylvania | 43 |  | 468,529 | 5.3\% | 87.0\% |
| Indiana | 59 |  | 406,490 | 4.6\% | 81.7\% |
| Tennessee | 41 |  | 345,290 | 3.9\% | 72.9\% |
| Virginia | 17 |  | 303,034 | 3.4\% | 87.2\% |
| South Carolina | 23 |  | 268,947 | 3.1\% | 94.0\% |
| Remaining 32 states ${ }^{(3)}$ | 366 |  | 3,267,239 | 36.9\% | 80.9\% |
|  | 941 | \$ | 8,589,697 | 97.1\% | 82.2\% |
| United Kingdom | 35 |  | 257,446 | 2.9\% |  |
| Total | 976 | \$ | 8,847,143 | 100.0\% |  |

(1) Excludes nine properties classified as assets held for sale (AHS)
(2) Includes a $\$ 19.2$ million lease inducement and excludes $\$ 23.2$ million (nine properties) classified as AHS
(3) Includes New York City 2nd Avenue development project
(4) As of December 31, 2016, TTM

Operator EBITDARM Coverage Distribution as a percentage of Rent/Debt Service—Based on 12/31/2016 TTM


Operator ebitdar Coverage Distribution as a percentage of Rent/Debt Service—Based on 12/31/2016 tTM


NOTE: Represents $93 \%$ of current rent/debt service which is representative of all stable properties. Stable properties include generally, any triple-net rental property unless it 1) is new development that is not yet complete/open; 2) has not yet stabilized and is still within 12 months following the budgeted stabilization date; 3 ) is held for sale and/or is slated for closure or to be sold; or 4) is slated to be transitioned or has transitioned to a new operator within the last 12 months.

Master Leases with Operator Ebitdar Coverage < 1.0x

| Investment Type | EBITDARM Coverage | EBITDAR Coverage | \% of Total Rent | Current on <br> Rent (1) | Subordinated Management Fees | Guaranty | Letter of Credit / Security Deposit |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| SNF | 1.28 | 0.96 | 6.5\% | Within 45 days | $\checkmark$ | $\checkmark$ |  |
| SNF | 0.82 | 0.47 | 1.4\% | $\checkmark$ |  | $\checkmark$ | $\checkmark$ |
| SNF/ALF | 0.83 | 0.59 | 1.4\% | $\checkmark$ | $\checkmark$ | $\checkmark$ | $\checkmark$ |
| SNF/ALF | 0.92 | 0.62 | 0.3\% | $\checkmark$ |  | $\checkmark$ | $\checkmark$ |
| SNF | 1.02 | 0.68 | 0.3\% | $\checkmark$ | $\checkmark$ | $\checkmark$ |  |
| Add'I 7 SNFs with EBITDAR Cov. <1.0 ${ }^{(2)}$ |  |  | 0.5\% | 6/7 | 2 / 7 | 6/7 | $7 / 7$ |
|  |  |  | 10.4\% |  |  |  |  |
| (1) Rent is current if < 30 days outstanding; measured on 5/2/17 |  |  |  |  |  |  |  |
| (2) Combined EBITDARM Coverage is $.90 x$ and combined EBITDAR Coverage is $.43 x$ |  |  |  |  |  |  |  |


| (\$ in Thousands) | Investment <br> Amount |  |
| :--- | :---: | :---: |
| 2012 Total Investments | $\$ 509,558$ |  |
| 2013 Total Investments | $\$ 620,858$ |  |
| 2014 Total Investments | $\$ 565,510$ |  |

Acquisition
Acquisition
Acquisition
Acquisition
Acquisition
Acquisition
Acquisition
Acquisition
Total Acq. \& Mtgs.
Construction-in-Progress
CAPEX Funding
2015 Total Investments
2016

## Capital Structure at April 30, 2017



Note: At March 31, 2017, Omega held approximately \$40.3MM of net cash and short-term investments (excludes UK balances)

1) Excludes $0.25 \%$ annual Facility Fee on the full commitment
2) Latest maturity given optional extensions provided in Agreements $\quad$ 4) Includes $\$ 150$ million add-on closed on $4 / 4 / 2017$
3) Fixed via swap at $3.80 \%$ effective beginning $12 / 30 / 2016$
4) New offering closed on $4 / 4 / 2017$

## Debt Maturities at April 30, 2017

| (\$ in thousands) | Secured Debt | Unsecured Debt |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | HUD <br> Mortgages |  <br> Term Loans ${ }^{(2)(3)}$ | Senior Notes ${ }^{(4)}$ | Sub Notes ${ }^{(5)}$ | Total <br> Debt Maturities |
| 2017 | - | - | - | - | - |
| 2018 | - | - | - | - | - |
| 2019 | - | 1,550,000 | - | - | 1,550,000 |
| 2020 | - | - | - | - | - |
| 2021 | - | 350,000 | - | 20,000 | 370,000 |
| 2022 |  | 250,000 |  |  | 250,000 |
| 2023 | - | - | 700,000 | - | 700,000 |
| Thereafter | 54,530 | - | 2,650,000 | - | 2,704,530 |
|  | 54,530 | 2,150,000 | 3,350,000 | 20,000 | 5,574,530 |

(1) Mortgages guaranteed by HUD (excludes net deferred financing costs of $\$ 0.6$ million)
(2) Reflected at $100 \%$ borrowing capacity (4) Excludes net discounts, deferred financing costs and a
(3) $\$ 1.55$ billion is comprised of a: $\$ 100$ million term loan to Omega's operating partnership, $\$ 200$ million Tranche A-1 term loan and $\$ 1.25$ billion revolving credit facility (excluding a $\$ 250$ million accordion feature and $\$ 5.1$ million net deferred financing costs) assuming the exercise of existing extension rights
\$1.5 million promissory note
(5) Excludes $\$ 0.5$ million of fair market valuation adjustments

Senior Unsecured Credit Ratings

|  | CUSIP \# | Rating Information |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  | S\&P | Moody's | Fitch |
| Common Stock | 681936100 |  |  |  |
| Senior Unsecured Debt |  |  |  |  |
| \$700M, 4.375\% 2023 Notes | 681936 BJ 8 | BBB- | Baa3 | BBB- |
| \$400M, 4.95\% 2024 Notes | 681936 BB 5 | BBB- | Baa3 | BBB- |
| \$250M, 4.50\% 2025 Notes | 681936 BD 1 | BBB- | Baa3 | BBB- |
| \$600M, 5.25\% 2026 Notes | 681936 BH 2 | BBB- | Baa3 | BBB- |
| \$700M, 4.50\% 2027 Notes | 681936 BF 6 | BBB- | Baa3 | BBB- |
| \$550M, 4.75\% 2028 Notes | 681936 BK 5 | BBB- | Baa3 | BBB- |
| Corporate Rating............................................. |  | BBB- |  |  |
| Outlook.............................................................. |  | Stable | Stable | Stable |
| Analyst(s) |  | Michael Souers | Lori Marks | Britton O. Costa |
|  |  | (212) 438-2508 | (212) 553-1098 | (212) 908-0524 |

## Selected Credit Facility Covenants ${ }^{(1)}$

| Quarter Ending | Consolidated |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Leverage <br> Ratio | Secured Leverage Ratio | Unsecured Leverage Ratio | Fixed Charge Cov. Ratio | Unsecured Interest Cov. Ratio | Tangible Net Worth |
| Requirement: | <= 60\% | <=30\% | < $=60 \%$ | $>=1.50$ to 1 | $>=2.00$ to 1 | >\$2,348MM |
| June 30, 2016 | 48\% | 3\% | 49\% | 5.3 | 5.0 | Pass |
| September 30, 2016 | 48\% | 1\% | 52\% | 5.3 | 4.3 | Pass |
| December 31, 2016 | 46\% | 1\% | 50\% | 5.3 | 4.5 | Pass |
| March 31, 2017 | 46\% | 1\% | 50\% | 5.2 | 4.3 | Pass |
| Status | Pass | Pass | Pass | Pass | Pass | Pass |

Selected Unsecured Note Covenants ${ }^{(1)}$

|  | Unencumbered <br> Debt / Adj. <br> Total Assets |  |  |
| :--- | :---: | :---: | :---: |
| Quarter Ending | Secured Debt / Adj. <br> Unsecured Debt | Total Assets |  |
| Requirement: | $<=60 \%$ | $>=150 \%$ | $<=40 \%$ |
| June 30, 2016 | $47 \%$ | $209 \%$ | $2 \%$ |
| September 30, 2016 | $48 \%$ | $202 \%$ | $0 \%$ |
| December 31, 2016 | $47 \%$ | $207 \%$ | $0 \%$ |
| March 31, 2017 | $47 \%$ | $206 \%$ | $0 \%$ |

(1) Covenants are based on calculations as defined in the Company's Credit Agreement and Senior Note Indentures

## Selected Credit Statistics



[^0]NOTE: See the Non-GAAP reconciliations provided at the end of this supplement and on our website at www.omegahealthcare.com under "Financial Information" then "Non-GAAP Financial Measures."

EQUITY IsSUANCE SUMMARY
(in thousands, except per share data)

| ESP/ATM Program | 2012 |  | 2013 |  | 2014 |  | 2015 |  | 2016 |  | 2017 |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Q1 | Q2 |  | Q3 |  | Q4 |  | YTD |
| Shares Issued |  | 3,398 |  |  |  | 6,504 |  |  |  | 1,848 |  | - |  | 656 |  | 228 |  | - |  | - |  |  | 227.50 |
| Average Price per Share | \$ | 23.47 | \$ | 30.48 |  |  | \$ | 34.33 |  |  | \$ | \$ | \$ | 31.10 | \$ | 31.12 | \$ | - | \$ | - | \$ | - | 31.12 |
| Gross Proceeds | \$ | \$9,749 |  | 198,220 | \$ | 63,452 | \$ | \$ | \$ | 20,392 | \$ | 7,079 | \$ | - | \$ | - | \$ | - | 7,079 |
| DRSPP and Waiver Program | 2012 |  | 2013 |  | 2014 |  | 2015 |  | YTD |  | 2017 |  |  |  |  |  |  |  |  |
|  |  |  |  | Q1 |  |  |  | Q2 |  |  |  | Q3 |  | Q4 | YTD |
| Shares Issued |  | 5,062 |  |  |  | 1,930 |  |  |  | 2,083 |  | 4,184 |  | 7,215 |  | 239 |  | - |  | - |  | - | 239.16 |
| Average Price per Share | \$ | 22.11 | \$ | 28.94 | \$ | 34.32 | \$ | \$ 36.06 | \$ | 33.27 | \$ | 30.67 | \$ | - | \$ | - | \$ | - | 30.67 |
| Gross Proceeds |  | \$111,941 | \$ | 55,872 | \$ | 71,502 |  | \$150,871 |  | 240,041 | \$ | 7,335 | \$ | - | \$ | - | \$ | - | 7,335 |
| Secondary | 2012 |  | 2013 |  | 2014 |  | 2015 |  | YTD |  | 2017 |  |  |  |  |  |  |  |  |
|  |  |  |  | Q1 |  |  |  | Q2 |  |  |  | Q3 |  | Q4 | YTD |
| Shares Issued |  | - |  |  |  | 2,875 |  |  |  | - |  | 10,925 |  | - |  | - |  | - |  | - |  | - | - |
| Average Price per Share | \$ | - | \$ | 29.48 | \$ | - |  | \$ 42.00 | \$ | - | \$ | - | \$ | - | \$ |  | \$ | - | - |
| Gross Proceeds | \$ | - | \$ | 84,755 | \$ | - |  | \$458,850 | \$ | - | \$ | - | \$ | - | \$ | - | \$ | - | - |
| Totals | 2012 |  | 2013 |  | 2014 |  | 2015 |  | YTD |  | 2017 |  |  |  |  |  |  |  |  |
|  |  |  |  | Q1 |  |  |  | Q2 |  |  |  | Q3 |  | Q4 | YTD |
| Shares Issued |  | 8,460 |  |  |  | 11,309 |  |  |  | 3,932 |  | 15,109 |  | 7,871 |  | 467 |  | - |  | - |  | - | 466.66 |
| Average Price per Share | \$ | 22.66 | \$ | 29.96 | \$ | 34.32 | \$ | \$ 40.36 | \$ | 33.09 | \$ | 30.89 | \$ | - | \$ | - | \$ | - | 30.89 |
| Gross Proceeds |  | 191,690 |  | \$338,847 |  | 134,954 |  | \$609,721 |  | 260,433 | \$ | 14,414 | \$ | - | \$ | - | \$ | - | 14,414 |

Percentages of adjusted total debt to adjusted book capitalization and adjusted total debt to total market capitalization at March 31,2017 were $50.8 \%$ and $39.1 \%$, respectively. Adjusted total debt is total debt plus the discount or less the premium derived from the sale of unsecured borrowings, deferred financing costs (net) and fair market value adjustment of assumed debt. Adjusted book capitalization is defined as adjusted total debt plus stockholders' equity and noncontrolling interest. Adjusted total debt, adjusted book capitalization and related ratios are non-GAAP financial measures. Total market capitalization is the total market value of our securities as of March 31, 2017 plus adjusted total debt.

## Unaudited <br> (In thousands)

|  | AtMarch 31, 2017 |  |
| :---: | :---: | :---: |
| Revolving line of credit. | \$ | 123,000 |
| Term loans. |  | 1,100,000 |
| Secured borrowings. |  | 54,636 |
| Unsecured borrowings. |  | 3,073,000 |
| FMV adjustment of assumption of debt |  | 460 |
| Premium/(discount) unsecured borrowings (net). |  | $(17,129)$ |
| Deferred financing costs (net). |  | $(33,102)$ |
| Total debt. | \$ | 4,300,865 |
| Deduct FMV adjustment of assumption of debt |  | (460) |
| Add back discount (deduct premium) on unsecured borrowings (net)...... |  | 17,129 |
| Add back deferred financing costs (net). |  | 33,102 |
| Adjusted total debt. | \$ | 4,350,636 |
| BOOK CAPITALIZATION............................................................ |  |  |
| Adjusted total debt. | \$ | 4,350,636 |
| Omega stockholders' equity |  | 3,863,494 |
| Noncontrolling interest |  | 351,028 |
| Adjusted book capitalization. | \$ | 8,565,158 |
| MARKET CAPITALIZATION....................................................... |  |  |
| Omega common shares and OP units outstanding at 3/31/2017............... |  | 205,575 |
| Market price of common stock at 3/31/2017.. | \$ | 32.99 |
| Market capitalization of common stock at 3/31/2017... |  | 6,781,919 |
| Market capitalization of publicly traded securities.................................. |  | 6,781,919 |
| Add adjusted total debt. |  | 4,350,636 |
| Total market capitalization. | \$ | 11,132,555 |
| Adjusted total debt / adjusted book capitalization........................ |  | 50.8\% |
| Adjusted total debt / total market capitalization......................... |  | 39.1\% |


|  | Quarter Ended | Ending Share Price | Div. * Yield | Quarterly |  |  |  |  |  | Omega AFFO Guidance ${ }^{1}$ | Annually |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | AFFO/ <br> Share | Dividend |  | Payout Ratio | FAD/ <br> Share | FAD Payout Ratio |  | AFFO/ <br> Share | $\begin{gathered} \% \\ \text { Change } \\ \hline \end{gathered}$ |  | $\begin{aligned} & \text { FAD/ } \\ & \text { Share } \end{aligned}$ | $\begin{gathered} \% \\ \text { Change } \end{gathered}$ | Annual Dividend | \% Change |
| 2007 | 3/31/2007 | \$17.15 | 6.1\% | \$ 0.3375 | \$ | 0.27 |  | \$0.3111 | 86.8\% | \$1.32-\$1.36 |  |  |  |  |  |  |  |
|  | 6/30/2007 | \$15.83 | 6.8\% | \$ 0.3365 |  | 0.27 | 80.2\% | \$0.3141 | 86.0\% |  |  |  |  |  |  |  |  |
|  | 9/30/2007 | \$15.53 | 7.0\% | \$ 0.3528 |  | 0.28 | 80.0\% | \$0.3299 | 84.9\% |  |  |  |  |  |  |  |  |
|  | 12/31/2007 | \$16.05 | 7.0\% | \$ 0.3535 |  | 0.29 | 82.0\% | \$0.3387 | 85.6\% |  | \$1.38 | 11.3\% |  | \$1.29 | 9.8\% | \$1.11 | 13.3\% |
| 2008 | 3/31/2008 | \$17.36 | 6.7\% | \$ 0.3639 | \$ | 0.30 | 82.4\% | \$0.3612 | 83.1\% | \$1.41-\$1.43 |  |  |  |  |  |  |  |
|  | 6/30/2008 | \$16.65 | 7.2\% | \$ 0.3816 |  | 0.30 | 78.6\% | \$0.3709 | 80.9\% |  |  |  |  |  |  |  |  |
|  | 9/30/2008 | \$19.66 | 6.1\% | \$ 0.3387 |  | 0.30 | 88.6\% | \$0.3079 | 97.4\% |  |  |  |  |  |  |  |  |
|  | 12/31/2008 | \$15.97 | 7.5\% | \$ 0.3702 |  | 0.30 | 81.0\% | \$0.3354 | 89.4\% |  | \$1.45 | 5.4\% |  | \$1.38 | 6.3\% | \$1.20 | 8.1\% |
| 2009 | 3/31/2009 | \$14.08 | 8.5\% | \$ 0.3701 | \$ | 0.30 | 81.1\% | \$0.3550 | 84.5\% | \$1.47-\$1.50 |  |  |  |  |  |  |  |
|  | 6/30/2009 | \$15.52 | 7.7\% | \$ 0.3714 |  | 0.30 | 80.8\% | \$0.3569 | 84.1\% |  |  |  |  |  |  |  |  |
|  | 9/30/2009 | \$16.02 | 7.5\% | \$ 0.3657 |  | 0.30 | 82.0\% | \$0.3529 | 85.0\% |  |  |  |  |  |  |  |  |
|  | 12/31/2009 | \$19.45 | 6.2\% | \$ 0.3604 |  | 0.32 | 88.8\% | \$0.3401 | 94.1\% |  | \$1.47 | 0.9\% |  | \$1.40 | 2.1\% | \$1.22 | 1.7\% |
| 2010 | 3/31/2010 | \$19.49 | 6.6\% | \$ 0.3766 | \$ | 0.32 | 85.0\% | \$0.3704 | 86.4\% | \$1.60-\$1.68 |  |  |  |  |  |  |  |
|  | 6/30/2010 | \$19.93 | 6.4\% | \$ 0.3652 |  | 0.36 | 98.6\% | \$0.3957 | 91.0\% |  |  |  |  |  |  |  |  |
|  | 9/30/2010 | \$22.45 | 6.4\% | \$ 0.4531 |  | 0.37 | 81.7\% | \$0.4218 | 87.7\% |  |  |  |  |  |  |  |  |
|  | 12/31/2010 | \$22.44 | 6.6\% | \$ 0.4566 |  | 0.37 | 81.0\% | \$0.4074 | 90.8\% |  | \$1.65 | 12.5\% |  | \$1.60 | 13.6\% | \$1.42 | 16.4\% |
| 2011 | 3/31/2011 | \$22.34 | 6.6\% | \$ 0.4432 | \$ | 0.38 | 85.7\% | \$0.4009 | 94.8\% | \$1.80-\$1.86 |  |  |  |  |  |  |  |
|  | 6/30/2011 | \$21.01 | 7.2\% | \$ 0.4748 |  | 0.40 | 84.2\% | \$0.4345 | 92.1\% |  |  |  |  |  |  |  |  |
|  | 9/30/2011 | \$15.93 | 10.0\% | \$ 0.4769 |  | 0.40 | 83.9\% | \$0.4392 | 91.1\% |  |  |  |  |  |  |  |  |
|  | 12/31/2011 | \$19.35 | 8.3\% | \$ 0.4963 |  | 0.41 | 82.6\% | \$0.4623 | 88.7\% |  | \$ 1.89 | 14.5\% |  | \$1.74 | 8.9\% | \$1.59 | 12.0\% |
| 2012 | 3/31/2012 | \$21.26 | 7.7\% | \$ 0.5469 | \$ | 0.42 | 76.8\% | \$0.4738 | 88.6\% | \$2.06-\$2.12 |  |  |  |  |  |  |  |
|  | 6/30/2012 | \$22.50 | 7.5\% | \$ 0.5252 |  | 0.42 | 80.0\% | \$0.4535 | 92.6\% |  |  |  |  |  |  |  |  |
|  | 9/30/2012 | \$22.73 | 7.4\% | \$ 0.5353 |  | 0.44 | 82.2\% | \$0.4702 | 93.6\% |  |  |  |  |  |  |  |  |
|  | 12/31/2012 | \$23.85 | 7.4\% | \$ 0.5776 |  | 0.45 | 77.9\% | \$0.5236 | 85.9\% |  | \$ 2.18 | 15.3\% |  | \$1.92 | 10.6\% | \$1.73 | 8.8\% |
| 2013 | 3/31/2013 | \$30.36 | 5.9\% | \$ 0.6313 | \$ | 0.46 | 72.9\% | \$0.5739 | 80.2\% | \$2.45-\$2.50 |  |  |  |  |  |  |  |
|  | 6/30/2013 | \$31.02 | 5.9\% | \$ 0.6227 |  | 0.47 | 75.5\% | \$0.5614 | 83.7\% |  |  |  |  |  |  |  |  |
|  | 9/30/2013 | \$29.87 | 6.3\% | \$ 0.6260 |  | 0.48 | 76.7\% | \$0.5682 | 84.5\% |  |  |  |  |  |  |  |  |
|  | 12/31/2013 | \$29.80 | 6.4\% | \$ 0.6471 |  | 0.49 | 75.7\% | \$0.5861 | 83.6\% |  | \$2.53 | 15.9\% |  | \$2.29 | 19.2\% | \$1.90 | 9.8\% |
| 2014 | 3/31/2014 | \$33.52 | 5.8\% | \$ 0.7112 | \$ | 0.50 | 70.3\% | \$0.6506 | 76.9\% | \$2.69-\$2.72 |  |  |  |  |  |  |  |
|  | 6/30/2014 | \$36.86 | 5.4\% | \$ 0.6859 |  | 0.51 | 74.4\% | \$0.6257 | 81.5\% |  |  |  |  |  |  |  |  |
|  | 9/30/2014 | \$34.19 | 6.0\% | \$ 0.7320 |  | 0.52 | 71.0\% | \$0.6690 | 77.7\% |  |  |  |  |  |  |  |  |
|  | 12/31/2014 | \$39.07 | 5.3\% | \$ 0.7232 |  | 0.53 | 73.3\% | \$0.6621 | 80.0\% |  | \$2.85 | 12.9\% | \$ | 2.61 | 13.9\% | \$2.06 | 8.4\% |
| 2015 | 3/31/2015 | \$40.57 | 5.2\% | \$ 0.7084 | \$ | 0.54 | 76.2\% | \$0.6492 | 83.2\% | \$2.98-\$3.04 |  |  |  |  |  |  |  |
|  | 6/30/2015 | \$34.33 | 6.3\% | \$ 0.7696 |  | 0.55 | 71.5\% | \$0.7000 | 78.6\% |  |  |  |  |  |  |  |  |
|  | 9/30/2015 | \$35.15 | 6.3\% | \$ 0.7913 |  | 0.56 | 70.8\% | \$0.7168 | 78.1\% |  |  |  |  |  |  |  |  |
|  | 12/31/2015 | \$34.98 | 6.4\% | \$ 0.8067 |  | 0.57 | 70.7\% | \$0.7237 | 78.8\% |  | \$3.08 | 7.8\% | \$ | 2.79 | 7.0\% | \$2.22 | 7.8\% |
| 2016 | 3/31/2016 | \$35.30 | 6.5\% | \$ 0.8336 | \$ | 0.58 | 69.6\% | \$0.7488 | 77.5\% | \$3.25-\$3.30 |  |  |  |  |  |  |  |
|  | 6/30/2016 | \$33.95 | 6.8\% | \$ 0.8684 |  | 0.60 | 69.1\% | \$0.7731 | 77.6\% |  |  |  |  |  |  |  |  |
|  | 9/30/2016 | \$35.45 | 6.8\% | \$ 0.8327 |  | 0.61 | 73.3\% | \$0.7477 | 81.6\% |  |  |  |  |  |  |  |  |
|  | 12/31/2016 | \$31.26 | 7.8\% | \$ 0.8803 |  | 0.62 | 70.4\% | \$0.7965 | 77.8\% |  | \$3.42 | 11.0\% |  | 3.07 | 9.9\% | \$2.41 | 8.6\% |
| 2017 | 3/31/2017 | \$32.99 | 7.5\% | \$ 0.8569 | \$ | 0.63 | 73.5\% | \$0.7730 | 81.5\% | \$3.40-\$3.44 |  |  |  |  |  |  |  |

1. Except for 2015, guidance provided at the beginning of each fiscal year

* Based on the annualized dividend announced the previous quarter

| No. of consecutive quarterly dividends paid since 2003: | 55 |
| :--- | :--- |
| No. of quarterly dividend increases since 2003: | 41 |
| No. of consecutive quarterly dividend increases: | 19 |

## 2017 Guidance: AFFO: <br> \$3.40-\$3.44 <br> FAD: $\quad \$ 3.10-\$ 3.14$

NOTE: See the Non-GAAP reconciliations provided at the end of this supplement and on our website at www.omegahealthcare.com under "Financial Information" then "Non-GAAP Financial Measures."

## 2017 AFFO and FAD Guidance and Reconciliation

The Company affirmed its 2017 annual Adjusted FFO available to common stockholders to be between $\$ 3.40$ and $\$ 3.44$ per diluted share. The Company also confirmed its 2017 FAD guidance to be between $\$ 3.10$ and $\$ 3.14$ per diluted share. The following table presents a reconciliation of Omega's guidance regarding Adjusted FFO and FAD to projected GAAP earnings.

## 2017 Annual Adjusted FFO and FAD Guidance Range ${ }^{(1)}$

| Net Income | Full Year |
| :--- | :---: |
| Depreciation | $\$ 1.86-\$ 1.90$ |
| Gain on assets sold | 1.40 |
| Real estate impairment | $(0.04)$ |
| FFO | $\mathbf{\$ 3 . 2 6 - \$ 3 . 3 0}$ |
| Adjustments: |  |
| $\quad$ Contractual settlement | $(0.05)$ |
| $\quad$ Provision for uncollectible accounts | 0.01 |
| Transaction costs | 0.00 |
| Interest - refinancing costs | 0.11 |
| Stock-based compensation expense | 0.07 |
| Adjusted FFO | $\$ 3.40-\$ 3.44$ |

Non-cash interest expense 0.07
Capitalized interest
Non-cash revenue
(0.34)

FAD
\$3.10-\$3.14
(1) The Company's Adjusted FFO and FAD guidance for 2017 includes approximately $\$ 100$ million of planned capital renovation projects; however, it excludes the impact of additional new investments. It also excludes the impact of gains and losses from the sale of assets, revenue from divestitures, certain revenue and expense items, interest refinancing expense, capital transactions, acquisition and merger related costs, provisions for uncollectible receivables, and stock-based compensation expense. The Company may, from time to time, update its publicly announced Adjusted FFO and FAD guidance, but it is not obligated to do so.

The Company's guidance is based on a number of assumptions, which are subject to change and many of which are outside the Company's control. If actual results vary from these assumptions, the Company's expectations may change. Without limiting the generality of the foregoing, the timing and completion of acquisitions, divestitures, capital and financing transactions, and variations in stock-based compensation expense may cause actual results to vary materially from our current expectations. There can be no assurance that the Company will achieve its projected results.

Unaudited (in thousands, except per share amounts)

|  | Three Months Ended March 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  |
| Revenue |  |  |  |  |
| Rental income | \$ | 192,537 | \$ | 176,703 |
| Income from direct financing leases................................ |  | 15,646 |  | 15,442 |
| Mortgage interest income. |  | 15,956 |  | 16,606 |
| Other investment income - net |  | 6,914 |  | 3,431 |
| Miscellaneous income |  | 691 |  | 697 |
| Total operating revenues |  | 231,744 |  | 212,879 |
| Expenses |  |  |  |  |
| Depreciation and amortization ....................................... |  | 69,993 |  | 62,433 |
| General and administrative........................................ |  | 12,524 |  | 10,455 |
| Acquisition costs |  | (41) |  | 3,771 |
| Impairment loss on real estate properties ........................ |  | 7,638 |  | 34,558 |
| Provision for uncollectible accounts................................ |  | 2,404 |  | 5,124 |
| Total operating expenses ................................................... |  | 92,518 |  | 116,341 |
| Income before other income and expense .......................... |  | 139,226 |  | 96,538 |
| Other income (expense) |  |  |  |  |
| Interest income.. |  | 4 |  | 8 |
| Interest expense |  | $(45,041)$ |  | $(37,222)$ |
| Interest - amortization of deferred financing costs .......... |  | $(2,502)$ |  | $(2,132)$ |
| Interest - refinancing costs |  | - |  | (298) |
| Contractual settlement. |  | 10,412 |  | - |
| Realized gain (loss) on foreign exchange.......................... |  | 61 |  | (22) |
| Total other expense ......................................................... |  | $(37,066)$ |  | $(39,666)$ |
| Income before gain on assets sold ..................................... |  | 102,160 |  | 56,872 |
| Gain on assets sold - net................................................... |  | 7,420 |  | 1,571 |
| Income from continuing operations ................................... |  | 109,580 |  | 58,443 |
| Income tax expense. |  | $(1,100)$ |  | (247) |
| Income from unconsolidated joint venture ...................... |  | 632 |  | - |
| Net income. |  | 109,112 |  | 58,196 |
| Net income attributable to noncontrolling interest ............... |  | $(4,672)$ |  | $(2,641)$ |
| Net income available to common stockholders .................... | \$ | 104,440 | \$ | 55,555 |
| Income per common share available to common stockholders: |  |  |  |  |
| Basic: |  |  |  |  |
| Net income available to common stockholders ................ | \$ | 0.53 | \$ | 0.30 |
| Diluted: |  |  |  |  |
| Net income. | \$ | 0.53 | \$ | 0.29 |
| Dividends declared per common share ................................ | \$ | 0.62 | \$ | 0.57 |
| Weighted-average shares outstanding, basic ....................... |  | 197,013 |  | 188,228 |
| Weighted-average shares outstanding, diluted ..................... |  | 206,174 |  | 198,350 |


|  | March 31, |  | December 31, |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  |
|  | (Unaudited) |  |  |  |
| ASSETS |  |  |  |  |
| Real estate properties |  |  |  |  |
| Real estate investments | \$ | 7,581,665 | \$ | 7,566,358 |
| Less accumulated depreciation |  | $(1,306,084)$ |  | $(1,240,336)$ |
| Real estate investments - net |  | 6,275,581 |  | 6,326,022 |
| Investments in direct financing leases - net............................... |  | 604,777 |  | 601,938 |
| Mortgage notes receivable - net .............................................. |  | 644,696 |  | 639,343 |
|  |  | 7,525,054 |  | 7,567,303 |
| Other investments - net |  | 255,899 |  | 256,846 |
| Investment in unconsolidated joint venture................................ |  | 40,152 |  | 48,776 |
| Assets held for sale - net |  | 23,245 |  | 52,868 |
| Total investments |  | 7,844,350 |  | 7,925,793 |
| Cash and cash equivalents |  | 40,349 |  | 93,687 |
| Restricted cash |  | 12,198 |  | 13,589 |
| Accounts receivable - net |  | 272,506 |  | 240,035 |
| Goodwill. |  | 643,692 |  | 643,474 |
| Other assets |  | 29,023 |  | 32,682 |
| Total assets | \$ | 8,842,118 | \$ | 8,949,260 |
| LIABILITIES AND EQUITY |  |  |  |  |
| Revolving line of credit................................................................. | \$ | 123,000 | \$ | 190,000 |
| Term loans - net. |  | 1,094,875 |  | 1,094,343 |
| Secured borrowings - net. |  | 54,052 |  | 54,365 |
| Unsecured borrowings - net. |  | 3,028,938 |  | 3,028,146 |
| Accrued expenses and other liabilities ........................................... |  | 316,985 |  | 360,514 |
| Deferred income taxes................................................................. |  | 9,746 |  | 9,906 |
| Total liabilities .......................................................................... |  | 4,627,596 |  | 4,737,274 |

Equity:
Common stock $\$ .10$ par value authorized - 350,000 shares, issued and outstanding - 196,761 shares as of March 31, 2017 and 196,142 as of December 31, 2016. $\qquad$

| 19,676 | 19,614 |
| ---: | ---: |
| $4,878,637$ | $4,861,408$ |
| $1,843,377$ | $1,738,937$ |
| $(2,829,718)$ | $(2,707,387)$ |
| $(48,478)$ | $(53,827)$ |
| $3,863,494$ | $3,858,745$ |
| 351,028 | 353,241 |
| $4,214,522$ | $4,211,986$ |
| $\$, 842,118$ | $\$$ |

Unaudited (in thousands)

|  |  | Three Months Ended March 31, |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  | 2017 |  | 2016 |
| Cash flows from operating activities |  |  |  |  |
| Net income | \$ | 109,112 | \$ | 58,196 |
| Adjustment to reconcile net income to net cash provided by operating activities: |  |  |  |  |
| Depreciation and amortization ............................................................................................. |  | 69,993 |  | 62,433 |
| Impairment loss on real estate properties ............................................................................... |  | 7,638 |  | 34,558 |
| Provision for uncollectible accounts ...................................................................................... |  | 2,404 |  | 5,124 |
| Refinancing costs and amortization of deferred financing costs.................................................. |  | 2,502 |  | 2,430 |
| Accretion of direct financing leases ....................................................................................... |  | $(3,016)$ |  | $(2,921)$ |
| Stock-based compensation expense |  | 3,744 |  | 2,778 |
| Gain on assets sold - net....................................................................................................... |  | $(7,420)$ |  | $(1,571)$ |
| Amortization of acquired in-place leases - net .......................................................................... |  | $(3,096)$ |  | $(4,300)$ |
| Effective yield receivable on mortgage notes.......................................................................... |  | (593) |  | (819) |
| Change in operating assets and liabilities - net: |  |  |  |  |
| Accounts receivable ............................................................................................................. |  | $(21,377)$ |  | 560 |
| Straight-line rent receivables ............................................................................................. |  | $(11,747)$ |  | $(9,947)$ |
| Lease inducements............................................................................................................... |  | 447 |  | 647 |
| Other operating assets and liabilities ...................................................................................... |  | $(34,653)$ |  | $(19,989)$ |
| Net cash provided by operating activities .......................................................................................... |  | 113,938 |  | 127,179 |
| Cash flows from investing activities |  |  |  |  |
| Acquisition of real estate. |  | $(7,574)$ |  | $(416,104)$ |
| Investments in construction in progress ................................................................................. |  | $(15,703)$ |  | $(16,316)$ |
| Investments in direct financing leases. |  | $(2,229)$ |  | - |
| Deposit to acquire real estate |  | - |  | $(113,816)$ |
| Placement of mortgage loans...................................................................................................... |  | $(5,749)$ |  | $(6,162)$ |
| Distributions from unconsolidated joint venture ........................................................................... |  | 8,587 |  | - |
| Proceeds from sale of real estate investments............................................................................... |  | 45,848 |  | 2,392 |
| Capital improvements to real estate investments ......................................................................... |  | $(8,199)$ |  | $(9,544)$ |
| Proceeds from other investments |  | 23,181 |  | 1,461 |
| Investments in other investments |  | $(22,144)$ |  | $(116,003)$ |
| Collection of mortgage principal .................................................................................................. |  | 333 |  | 312 |
| Net cash provided by (used in) investing activities ............................................................................. |  | 16,351 |  | $(673,780)$ |
| Cash flows from financing activities |  |  |  |  |
| Proceeds from credit facility borrowings ..................................................................................... |  | 148,000 |  | 670,000 |
| Payments on credit facility borrowings ......................................................................................... |  | $(215,000)$ |  | $(370,000)$ |
| Receipts of other long-term borrowings ..................................................................................... |  | - |  | 350,000 |
| Payments of other long-term borrowings..................................................................................... |  | (318) |  | (309) |
| Payments of financing related costs ............................................................................................. |  | (563) |  | $(3,576)$ |
| Receipts from dividend reinvestment plan ................................................................................... |  | 7,335 |  | 19,596 |
| Payments for exercised options and restricted stock..................................................................... |  | $(2,120)$ |  | $(2,381)$ |
| Net proceeds from issuance of common stock ............................................................................ |  | 6,759 |  | - |
| Dividends paid .......................................................................................................................... |  | $(122,272)$ |  | $(107,500)$ |
| Redemption of OP Units.............................................................................................................. |  | (56) |  | (10) |
| Distributions to OP Unit Holders .................................................................................................. |  | $(5,554)$ |  | $(5,131)$ |
| Net cash (used in) provided by financing activities ............................................................................. |  | $(183,789)$ |  | 550,689 |
| Effect of foreign currency translation on cash and cash equivalents................................................. |  | 162 |  | (105) |
| (Decrease) increase in cash and cash equivalents............................................................................... |  | $(53,338)$ |  | 3,983 |
| Cash and cash equivalents at beginning of period ............................................................................... |  | 93,687 |  | 5,424 |
| Cash and cash equivalents at end of period ...................................................................................... | \$ | 40,349 | \$ | 9,407 |

Net Income, FFO, Adjusted FFO and FAD<br>(unaudited)

(in thousands, except per share data)

|  | Three Months Ended March 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  |
| Net income. | \$ | 109,112 | \$ | 58,196 |
| Deduct gain from real estate dispositions |  | $(7,420)$ |  | $(1,571)$ |
| Sub - total. |  | 101,692 |  | 56,625 |
| Elimination of non-cash items included in net income: |  |  |  |  |
| Depreciation and amortization.... |  | 69,993 |  | 62,433 |
| Depreciation - unconsolidated joint venture .... |  | 1,658 |  | - |
| Add back non-cash provision for impairments on real estate properties |  | 7.638 |  | 34.558 |
| Funds from operations................................................... | \$ | 180,981 | \$ | 153,616 |
| Weighted-average common shares outstanding, basic.......... |  | 197,013 |  | 188,228 |
| Restricted stock and PRSUs ........................................... |  | 347 |  | 1,175 |
| Omega OP Units.. |  | 8,814 |  | 8,947 |
| Weighted-average common shares outstanding, diluted ....... |  | 206,174 |  | 198,350 |
| Funds from operations available per share.......................... | \$ | 0.88 | \$ | 0.77 |
| Adjustments to calculate adjusted funds from operations: |  |  |  |  |
| Funds from operations available to common | \$ | 180,981 | \$ | 153,616 |
| Deduct one-time revenue ...................................... |  | - |  | (235) |
| Deduct contractual settlement. |  | $(10,412)$ |  | - |
| (Deduct) add back acquisition costs ................................. |  | (41) |  | 3,771 |
| Add back provision for uncollectible accounts.................... |  | 2,404 |  | 5,124 |
| Add back interest refinancing expense .............................. |  | - |  | 298 |
| Add back non-cash stock-based compensation expense...... |  | 3,744 |  | 2,778 |
| Adjusted funds from operations .......................................... | \$ | 176,676 | \$ | 165,352 |
| Adjustments to calculate funds available for distribution: |  |  |  |  |
| Non-cash interest expense............................................. |  | 2,810 |  | 2,100 |
| Capitalized interest ...................................................... |  | $(1,989)$ |  | $(1,720)$ |
| Non-cash revenues ...................................................... |  | $(18,129)$ |  | $(17,209)$ |
| Funds available for distribution......................................... | \$ | 159,368 | \$ | 148,523 |

Funds From Operations ("FFO"), Adjusted FFO and FAD are non-GAAP financial measures. For purposes of the Securities and Exchange Commission's Regulation G, a non-GAAP financial measure is a numerical measure of a company's historical or future financial performance, financial position or cash flows that exclude amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable financial measure calculated and presented in accordance with GAAP in the statement of operations, balance sheet or statement of cash flows (or equivalent statements) of the company, or include amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable financial measure so calculated and presented. As used in this press release, GAAP refers to generally accepted accounting principles in the United States of America. Pursuant to the requirements of Regulation G, the Company has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The Company calculates and reports FFO in accordance with the definition and interpretive guidelines issued by the National Association of Real Estate Investment Trusts ("NAREIT"), and consequently, FFO is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairments on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures. Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect funds from operations on the same basis. The Company believes that FFO, Adjusted FFO and FAD are important supplemental measures of its operating performance. Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions. The term FFO was designed by the real estate industry to address this issue. FFO described herein is not necessarily comparable to FFO of other real estate investment trusts, or REITs, that do not use the same definition or implementation guidelines or interpret the standards differently from the Company.

Adjusted FFO is calculated as FFO excluding the impact of non-cash stock-based compensation and certain revenue and expense items identified above. FAD is calculated as Adjusted FFO less non-cash interest expense and non-cash revenue, such as straight-line rent. The Company believes these measures provide an enhanced measure of the operating performance of the Company's core portfolio as a REIT. The Company's computation of Adjusted FFO and FAD are not comparable to the NAREIT definition of FFO or to similar measures reported by other REITs, but the Company believes that they are appropriate measures for this Company.

The Company uses these non-GAAP measures among the criteria to measure the operating performance of its business. The Company also uses Adjusted FFO among the performance metrics for performance-based compensation of officers. The Company further believes that by excluding the effect of depreciation, amortization, impairments on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, FFO can facilitate comparisons of operating performance between periods and between other REITs. The Company offers these measures to assist the users of its financial statements in analyzing its operating performance and not as measures of liquidity or cash flow. These non-GAAP measures are not measures of financial performance under GAAP and should not be considered as measures of liquidity, alternatives to net income or indicators of any other performance measure determined in accordance with GAAP. Investors and potential investors in the Company's securities should not rely on these non-GAAP measures as substitutes for any GAAP measure, including net income.

For information regarding Adjusted Total Debt and Adjusted Book Capitalization, see the "Capitalization: Book and Market Capitalization with Ratios" section of this supplement.

## EBITDA Reconciliation and Debt Coverage Ratio Calculation

Our ratios of Funded Debt to annualized EBITDA, Funded Debt to adjusted annualized EBITDA and Funded Debt to adjusted pro forma annualized EBITDA as of March 31, 2017 were $4.70 x, 4.78 x$ and $4.78 x$, respectively. EBITDA is defined as earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA eliminates items such as acquisition and merger related costs and stock-based compensation expense and adds back certain non-cash expenses, if any, to EBITDA. Adjusted pro forma EBITDA adds to adjusted EBITDA the incremental EBITDA from new investments made during the 1st quarter assuming a January 1 purchase date. EBITDA, adjusted EBITDA, adjusted pro forma EBITDA and related ratios are non-GAAP financial measures. Annualized EBITDA, adjusted annualized EBITDA and adjusted pro forma annualized EBITDA assume the current quarter results multiplied by four, and are not projections of future performance. Below is the reconciliation of EBITDA and adjusted EBITDA to net income.


## EBITDA Reconciliation and Fixed Charge and Interest Coverage Ratio Calculation

Our EBITDA to total interest expense ratio, adjusted EBITDA to total interest expense ratio and adjusted EBITDA to fixed charges as of March 31, 2017 were $4.8 x, 4.7 x$ and $4.5 x$, respectively. Fixed charge coverage is the ratio determined by dividing EBITDA by our fixed charges. EBITDA is defined as earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA eliminates items such as acquisition and merger related costs and stock-based compensation expense and adds back certain non-cash expenses, if any, to EBITDA.

Fixed charges consist of interest expense, amortization of other non-cash interest charges, amortization of deferred financing costs and refinancing costs. EBITDA, adjusted EBITDA and interest expense ratio are non-GAAP measures. Below is the reconciliation of EBITDA to net income.

## Unaudited <br> (In thousands)

|  | Three Months Ended March 31, 2017 |  |
| :---: | :---: | :---: |
| Net income. | \$ | 109,112 |
| Depreciation and amortization. |  | 69,993 |
| Depreciation - unconsolidated joint venture |  | 1,658 |
| Interest. |  | 47,543 |
| Income taxes. |  | 1,100 |
| EBITDA.. | \$ | 229,406 |
| Deduct gain on assets sold - net. |  | $(7,420)$ |
| Deduct contractual settlement. |  | $(10,412)$ |
| Deduct acquisition and merger related costs. |  | (41) |
| Add back non-cash provision for uncollectible accounts.. |  | 2,404 |
| Add back non-cash provision for impairments on real estate properties.................. |  | 7,638 |
| Add back stock-based compensation expense. |  | 3,744 |
| Adjusted EBITDA. | \$ | 225,319 |
| FIXED CHARGES |  |  |
| Interest expense. | \$ | 45,041 |
| Amortization of non-cash deferred financing charges. |  | 2,502 |
| Total interest expense. | \$ | 47,543 |
| Add back: capitalized interest.. |  | 1,989 |
| Total fixed charges. | \$ | 49,532 |
| EBITDA / total interest expense ratio. |  | 4.8 x |
| Adjusted EBITDA / total interest expense ratio........................................ |  | 4.7 x |
| Adjusted EBITDA / fixed charge coverage ratio........................................ |  | 4.5 x |

## PORTFOLIO METRICS

EBITDARM Coverage: Represents EBITDARM of our operators, defined as earnings before interest, taxes, depreciation, amortization, Rent expense and management fees for the applicable period, divided by the total Rent paid to the Company by its operators during such period.

EBITDAR Coverage: Represents EBITDAR of our operators, defined as earnings before interest, taxes, depreciation, amortization, and Rent expense for the applicable period, divided by the total Rent paid to the Company by its operators during such period. Assumes a management fee of $4 \%$.

Portfolio Occupancy: Represents the average daily number of beds at the Company's properties that are occupied during the applicable period divided by the total number of total operating beds at the Company's properties that are available for use during the applicable period.

Property Type: ALF = assisted living facility; SNF = skilled nursing facility
Portfolio metrics and other statistics are not derived from Omega's financial statements but are operating statistics that the Company derives from reports that it receives from its operators pursuant to Omega's triple-net leases and mortgages. As a result, the Company's portfolio metrics typically lag its own financial statements by approximately one quarter. Portfolio metrics exclude assets held for sale, closed properties, properties under construction and, with certain exceptions for shorter periods, properties within 24 months of completion of construction.

Rent: Refers to the total monthly rent and mortgage interest due under all of the Company's lease and mortgage agreements as of the date specified, calculated based on the first full month following the specified date. Omega calculates "annualized rent" for properties during a period by utilizing the amount of rent under contract as of the last day of the period and assumes that amount of rent was received in respect of such property throughout the entire period.

## NON-GAAP FINANCIAL MEASURES

FFO: Funds from Operations (FFO), is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairments on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures.

AFFO: Adjusted FFO (AFFO) is calculated as FFO excluding the impact of non-cash stock-based compensation and certain revenue and expense items identified above.

FAD: Funds Available for Distribution (FAD) is calculated as AFFO less non-cash interest expense and non-cash revenue, such as straight-line rent.

A further discussion of the Non-GAAP Financial Measures defined above is provided on page 18 of this supplement.


[^0]:    1) EBITDA is adjusted for non-cash and one-time items, and for leverage ratios includes proforma revenue for investments made in quarter/year; Total Net Funded Debt excludes outstanding L/C's, if any, premium on bonds, fair market valuations \& FIN46 consolidations and net of cash \& cash equivalents. EBITDA for "Qtr. Ending" periods are annualized
    2) Fixed charges includes scheduled amortizations, amortization of deferred financing charges and capitalized interest
